7-甲基蝶啶 | 936-40-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 中文名称: 7-甲基蝶啶
• 英文名称: 7-methylpteridine
• 英文别名: 7-methyl-pteridine；7-Methyl-pteridin；7-Methylpteridin
• CAS: 936-40-3
• 化学式: C₇H₆N₄
• 分子量: 146.151
• InChiKey: KOCYTWBTXZOUFS-UHFFFAOYSA-N

物化性质

• 熔点：
  196.5°C
• 沸点：
  255.75°C (rough estimate)
• 密度：
  1.2955 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-甲基蝶啶 在 potassium permanganate 、 氨 作用下， 反应 4.0h， 以88%的产率得到4-氨基-7-甲基蝶啶
  参考文献：
  名称：

  Sladowska, H.; De Meester, J. W. G.; Plas, H. C. van der, Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 477 - 480

  摘要：

  DOI：
• 作为产物：
  描述：

  4,5-二氨基嘧啶 、 丙酮醛 在 水 、 sodium hydrogensulfite 作用下， 生成 7-甲基蝶啶
  参考文献：
  名称：

  Albert et al., Journal of the Chemical Society, 1954, p. 3832,3833

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C (VHC) ET LEURS UTILISATIONS EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015197028A1

  公开（公告）日：2015-12-30

  Provided herein are compounds of Formula (I), or a stereoisomer, a geometric isomer, an enantiomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which are used in the treatment of HCV infection or hepatitis C. Provided herein also are pharmaceutical compositions containing such compounds and methods of using the compound of the present invention or pharmaceutical compositions thereof to treat HCV infection or hepatitis C.

  本文提供了式（I）的化合物，或其立体异构体、几何异构体、对映体、互变异构体、N-氧化物、水合物、溶剂合物、代谢物、药学上可接受的盐或其前药，用于治疗HCV感染或丙型肝炎。本文还提供了含有这些化合物的药物组合物以及使用本发明的化合物或其药物组合物治疗HCV感染或丙型肝炎的方法。
• New Piperazine Compound and Use Thereof as a HCV Polymerase Inhibitor
  申请人：Abe Hiroyuki

  公开号：US20080081818A1

  公开（公告）日：2008-04-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的化合物，其中每个符号如规范中定义，或其药学上可接受的盐，或其溶剂化合物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，并且可用作预防或治疗丙型肝炎的药剂。
• [EN] HERBICIDAL COMPOUNDS<br/>[FR] COMPOSÉS HERBICIDES
  申请人：SYNGENTA CROP PROTECTION AG

  公开号：WO2021058592A1

  公开（公告）日：2021-04-01

  Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

  式（I）中的化合物，其中取代基如权利要求1中定义的那样，作为农药是有用的，特别是作为除草剂。
• AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES
  申请人：OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"

  公开号：US20170183318A1

  公开（公告）日：2017-06-29

  The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

  本发明涉及医学，包括一种用于预防和治疗由RNA-和DNA-含病毒引起的疾病以及相关疾病的方法，其中该方法包括使用通式I的化合物或其药用可接受盐的有效量。该发明还涉及制备上述化合物的方法，用于预防或治疗由RNA-和DNA-含病毒引起的疾病的药物组合物，该组合物包括通式I的化合物或其药用可接受盐的有效量。该发明解决了提供一种新型药剂的目标，用于治疗属于肠病毒、副呼吸道病毒、呼吸道病毒、呼吸道病毒或阿尔法冠状病毒属的RNA-含病毒引起的疾病，和/或属于腺病毒科和/或疱疹病毒科的DNA-含病毒引起的疾病，并在预防和治疗哮喘急性发作、慢性阻塞性肺疾病、黏液囊病、结膜炎、胃肠炎、肝炎、心肌炎；在预防和治疗流涕、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道梗阻综合征方面具有有效性。
• New utilities of tricyclic compounds
  申请人：Ishizuka Natsuki

  公开号：US20080318958A1

  公开（公告）日：2008-12-25

  Pharmaceutical compositions for enhancing the expression of apoAI are provided, which are used as medicaments for treatment of cardiovascular diseases on the basis of improving the functions of HDL. Pharmaceutical compositions for enhancing the expression of apoAI which comprises a compound of formula (I): in which X 1 and X 1 are independently an aryl or heteroaryl that may be optionally substituted, a hydrogen, a halogen, or the like; ring A is a benzene ring or 6-membered aromatic heterocyclic ring containing 1 to 3 N atoms that may be optionally condensed with another aromatic ring; R 1 to R 4 are independently a hydrogen, a halogen, a lower alkyl, a lower alkoxy or the like; a prodrug thereof, a pharmaceutically acceptable salt or solvate of them are disclosed.

  提供用于增强apoAI表达的药物组合物，用于改善HDL功能，作为治疗心血管疾病的药物。药物组合物用于增强apoAI表达，其中包括式(I)的化合物：其中X1和X2独立地是芳基或杂芳基，可以选择性地被取代，氢，卤素等；环A是苯环或含有1至3个N原子的6元芳杂环，可以选择性地与另一个芳香环融合；R1至R4独立地是氢，卤素，低碳基，低碳氧基或类似物；其前药，药学上可接受的盐或溶剂也被披露。